Extent, dynamics and mechanisms of Plasmodium vivax immune evasion caused by PvDBP gene amplification
PvDBP基因扩增引起间日疟原虫免疫逃避的程度、动态及机制
基本信息
- 批准号:10734028
- 负责人:
- 金额:$ 62.62万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-07-17 至 2028-06-30
- 项目状态:未结题
- 来源:
- 关键词:AdultAllelesAntibodiesAreaBiomassBloodCambodiaCambodianChildClinicalDataDevelopmentDiagnosticDistantEastern AfricaEnrollmentEpidemiologyEpitopesErythrocytesEthiopiaEvolutionExposure toFlow CytometryFrequenciesGene AmplificationGenesGeneticGenetic PolymorphismGenomic approachGenomicsGoalsHumanHumoral ImmunitiesImmune EvasionImmunityImmunoglobulin GImmunologic TestsIn VitroIndividualInfectionInvadedLengthLigandsLongitudinal cohortMalariaMalaria VaccinesMeasuresMediatingMolecularParasitemiaParasitesParticipantPhase II Clinical TrialsPhenotypePlasmodium vivaxPopulationPopulation DynamicsPrevalenceProcessProtein IsoformsProteinsSerologySeverity of illnessSideSoutheastern AsiaStructureSurfaceTestingTimeTranscendTransgenic OrganismsVaccinesVariantVivax MalariaWestern BlottingWorkdeep sequencingdesignfollow-uphuman monoclonal antibodiesimmunological statusin vivolive cell imagingneutralizing antibodyparticipant enrollmentpathogenphase II trialprospective testreceptorresilienceresponsesuccesstime usetranscriptome sequencingvaccine developmentvaccine strategy
项目摘要
Elimination of Plasmodium vivax (Pv) malaria parasites would greatly benefit from a blood-stage vaccine. PvDBP
is a parasite ligand involved in erythrocyte invasion through the interaction with its human receptor, the Duffy
protein. This interaction is critical for the parasite’s entry making PvDBP the most advanced candidate for a
blood-stage vaccine with Phase II clinical trials undergoing. Recent work has identified and characterized human
monoclonal antibodies (humabs) that allow strain-transcending neutralization of parasites regardless of their
PvDBP sequence diversity. However, we have demonstrated that Pv collected in Cambodia with multiple copies
of the PvDBP gene were able to overcome in vitro neutralization by these humabs. These observations provided
the first evidence for an evolutionary advantage for pvdbp amplification, widespread in Pv populations, and
created a new paradigm in which to consider pathogen immune evasion mechanisms. These results raise the
concern that implementation of a PvDBP vaccine may select for multi-pvdbp copy parasites. The overall goal
of this proposal is precisely to determine if pvdbp amplification will likely compromise a PvDBP vaccine
strategy. The first Specific Aim (SA) is to determine to what extent multi-pvdbp copy parasites genetically distant
from Cambodian isolates respond to anti-PvDBP humabs and to evaluate if pvdbp amplification is associated to
Duffy polymorphisms in human populations. By evaluating the in vitro neutralization by anti-PvDBP humabs of
single and multi-pvdbp copy parasites from Ethiopia, we will be able to evaluate the extent of the immune evasion
phenotype conferred by pvdbp amplification described with Cambodian Pv. By (i) associating in vitro invasion
rates with the full-length Duffy sequences of invaded erythrocytes, and (ii) prospectively testing for association
between pvdbp copy number and human Duffy sequences in participants enrolled in longitudinal cohorts in
Cambodia and in Ethiopia, we will be able to determine the relation between pvdbp amplification and Duffy
human polymorphism. Our second SA will be to evaluate the within-hosts and within-population dynamics of
pvdbp amplification over time. Through the analysis of the serological dynamics of our longitudinal cohorts’
participants, the measure of Pv infections and the pvdbp copy number of infecting parasites, we will be able to
test if the gene amplification is selected in vivo by the immune status of human hosts and how it correlates with
changes in Pv prevalence in the population. In vitro experimental evolution of Pk lines will provide complementary
evidence for selection of pvdbp amplification by anti-PvDBP humabs. Our third SA will be to decipher the
molecular mechanisms enabling multi-copy parasites to evade anti-PvDBP humabs’ neutralization. We will
specifically test if immune evasion results from increased protein quantity produced by multi-copy parasites
and/or from epitope variations through multiple, different alleles and variants present simultaneously in a given
parasite. Through a combination of phenotyping and genomic approaches, our results will provide invaluable
data to inform on strategies to overcome this immune evasion in the context of vaccine development.
.
消灭间日疟原虫(Pv)疟疾寄生虫将大大受益于血液阶段疫苗。PvDBP
是一种寄生虫配体,通过与其人类受体达菲相互作用参与红细胞侵入
蛋白这种相互作用对于寄生虫的进入至关重要,使PvDBP成为最先进的候选者。
血液阶段疫苗,正在进行第二阶段临床试验。最近的工作已经确定并表征了人类
单克隆抗体(humab),允许超越菌株的寄生虫中和,而不管它们的
PvDBP序列多样性。然而,我们已经证明,在柬埔寨收集的Pv有多个副本,
的PvDBP基因能够克服体外中和这些humab。这些意见提供了
pvdbp扩增具有进化优势的第一个证据,广泛存在于Pv种群中,
创造了一个新的范式,考虑病原体免疫逃避机制。这些结果提高了
担心实施PvDBP疫苗可能选择多拷贝的pvDBP寄生虫。总目标
该提议的目的是确定pvDBP扩增是否可能损害PvDBP疫苗
战略第一个特定目的(SA)是确定多pvdbp拷贝寄生虫遗传距离的程度
柬埔寨分离株对抗PvDBP humab应答,并评估pvDBP扩增是否与
人类群体中的Duffy多态性。通过评价抗PvDBP humab的体外中和作用,
单和多pvdbp副本寄生虫从埃塞俄比亚,我们将能够评估免疫逃避的程度
柬埔寨Pv.通过(i)将体外侵袭
率与入侵红细胞的全长Duffy序列,和(ii)前瞻性测试的关联
pvdbp拷贝数和人Duffy序列之间的关系,
在柬埔寨和埃塞俄比亚,我们将能够确定pvdbp扩增和达菲之间的关系,
人类多态性我们的第二个SA将是评估宿主内和种群内的动态,
pvDBP随时间的扩增。通过对我们的纵向队列的血清学动态分析,
参与者,Pv感染的测量和感染寄生虫的pvdbp拷贝数,我们将能够
测试基因扩增是否是由人类宿主的免疫状态在体内选择的,以及它与
人群中PV患病率的变化。PK系的体外实验进化将提供补充
通过抗PvDBP humab选择pvDBP扩增的证据。我们的第三个SA将破译
使多拷贝寄生虫能够逃避抗PvDBP humab中和的分子机制。我们将
特异性测试免疫逃避是否由多拷贝寄生虫产生的蛋白质量增加引起
和/或通过在给定的表位中同时存在的多个不同的等位基因和变体的表位变异
寄生虫通过表型分析和基因组学方法的结合,我们的结果将提供宝贵的
数据,以告知在疫苗开发的背景下克服这种免疫逃避的策略。
.
项目成果
期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Prevalence and characteristics of Plasmodium vivax Gametocytes in Duffy-positive and Duffy-negative populations across Ethiopia.
埃塞俄比亚达菲阳性和达菲阴性人群中间日疟原虫配子细胞的患病率和特征。
- DOI:10.1101/2023.12.10.23299780
- 发表时间:2023
- 期刊:
- 影响因子:0
- 作者:Little,Ebony;Shenkutie,TassewT;Negash,MesheshaTsigie;Abagero,BekaR;Abebe,Abnet;Popovici,Jean;Mekasha,Sindew;Lo,Eugenia
- 通讯作者:Lo,Eugenia
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Eugenia Lo其他文献
Eugenia Lo的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Eugenia Lo', 18)}}的其他基金
Plasmodium vivax Erythrocyte Invasion Mechanisms and Humoral Immune Response in Duffy Negative Africans
达菲阴性非洲人间日疟原虫红细胞侵袭机制和体液免疫反应
- 批准号:
10445540 - 财政年份:2022
- 资助金额:
$ 62.62万 - 项目类别:
Functional assays of Plasmodium vivax DBP, EBP, and RBP2b in erythrocyte invasion in Duffy-Negative Africans
间日疟原虫 DBP、EBP 和 RBP2b 在达菲阴性非洲人红细胞侵袭中的功能测定
- 批准号:
10598381 - 财政年份:2022
- 资助金额:
$ 62.62万 - 项目类别:
Plasmodium vivax Erythrocyte Invasion Mechanisms and Humoral Immune Response in Duffy Negative Africans
达菲阴性非洲人间日疟原虫红细胞侵袭机制和体液免疫反应
- 批准号:
10569567 - 财政年份:2022
- 资助金额:
$ 62.62万 - 项目类别:
相似海外基金
Linkage of HIV amino acid variants to protective host alleles at CHD1L and HLA class I loci in an African population
非洲人群中 HIV 氨基酸变异与 CHD1L 和 HLA I 类基因座的保护性宿主等位基因的关联
- 批准号:
502556 - 财政年份:2024
- 资助金额:
$ 62.62万 - 项目类别:
Olfactory Epithelium Responses to Human APOE Alleles
嗅觉上皮对人类 APOE 等位基因的反应
- 批准号:
10659303 - 财政年份:2023
- 资助金额:
$ 62.62万 - 项目类别:
Deeply analyzing MHC class I-restricted peptide presentation mechanistics across alleles, pathways, and disease coupled with TCR discovery/characterization
深入分析跨等位基因、通路和疾病的 MHC I 类限制性肽呈递机制以及 TCR 发现/表征
- 批准号:
10674405 - 财政年份:2023
- 资助金额:
$ 62.62万 - 项目类别:
An off-the-shelf tumor cell vaccine with HLA-matching alleles for the personalized treatment of advanced solid tumors
具有 HLA 匹配等位基因的现成肿瘤细胞疫苗,用于晚期实体瘤的个性化治疗
- 批准号:
10758772 - 财政年份:2023
- 资助金额:
$ 62.62万 - 项目类别:
Identifying genetic variants that modify the effect size of ApoE alleles on late-onset Alzheimer's disease risk
识别改变 ApoE 等位基因对迟发性阿尔茨海默病风险影响大小的遗传变异
- 批准号:
10676499 - 财政年份:2023
- 资助金额:
$ 62.62万 - 项目类别:
New statistical approaches to mapping the functional impact of HLA alleles in multimodal complex disease datasets
绘制多模式复杂疾病数据集中 HLA 等位基因功能影响的新统计方法
- 批准号:
2748611 - 财政年份:2022
- 资助金额:
$ 62.62万 - 项目类别:
Studentship
Recessive lethal alleles linked to seed abortion and their effect on fruit development in blueberries
与种子败育相关的隐性致死等位基因及其对蓝莓果实发育的影响
- 批准号:
22K05630 - 财政年份:2022
- 资助金额:
$ 62.62万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Genome and epigenome editing of induced pluripotent stem cells for investigating osteoarthritis risk alleles
诱导多能干细胞的基因组和表观基因组编辑用于研究骨关节炎风险等位基因
- 批准号:
10532032 - 财政年份:2022
- 资助金额:
$ 62.62万 - 项目类别:
Investigating the Effect of APOE Alleles on Neuro-Immunity of Human Brain Borders in Normal Aging and Alzheimer's Disease Using Single-Cell Multi-Omics and In Vitro Organoids
使用单细胞多组学和体外类器官研究 APOE 等位基因对正常衰老和阿尔茨海默病中人脑边界神经免疫的影响
- 批准号:
10525070 - 财政年份:2022
- 资助金额:
$ 62.62万 - 项目类别:
Leveraging the Evolutionary History to Improve Identification of Trait-Associated Alleles and Risk Stratification Models in Native Hawaiians
利用进化历史来改进夏威夷原住民性状相关等位基因的识别和风险分层模型
- 批准号:
10689017 - 财政年份:2022
- 资助金额:
$ 62.62万 - 项目类别: